TCON News and Press, TRACON Pharmaceuticals Inc. From 05/29/20

Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled in TRACON’s Pivotal ENVASARC Trial   of Envafolimab as a Single Agent and in Combination with Yervoy Pivotal ENVASARC Trial to Start in the Second Half of 2020 SAN DIEGO, May 29, 2020 (GLO...

Mmtec (NASDAQ: MTC ) +168%  on FY results . More news on: Mmtec, Inc., Sky Solar Holdings, Ltd., Cellectar Biosciences, Inc., Stocks on the move, , Read more ...

Envafolimab Demonstrated a 30% Confirmed Objective Response Rate (ORR) by RECIST by Independent Central Review in Patients with Advanced Refractory MSI-H/dMMR Colorectal and Gastric Cancer ORR and Other Data will be Updated at ASCO TRACON Expects to Initiate its Pivotal ENVASARC T...

TRACON Pharmaceuticals (TCON) Q1 2020 Earnings Conference Call May 13, 2020 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Accounting Officer and Head of Finance Conference Call Participants Maury Raycr...

Tracon (NASDAQ: TCON ): Q1 GAAP EPS of -$0.78 beats by $0.35 . Cash and cash equivalents were $14.1M Press Release More news on: TRACON Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to...

Cellect Biotechnology (NASDAQ: APOP ) +126%  on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...

TRACON Pharmaceuticals (NASDAQ: TCON ) is on go with a pivotal trial, ENVASARC, evaluating lead drug envafolimab in soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma and myxofibrosarcoma after meeting with the FDA to clarify the key elements of the study. More news on:...

Company Reaches Agreement with Regulatory Agency on Key Elements  of ENVASARC Trial Pivotal Trial Expected to Begin in Second Half of 2020 SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on th...

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. compan...